* Denosumab has been approved under the trade name Xgeva for use in patients with metastasized cancer to help prevent bone-related events.
* Clinical trials found denosumab to be superior to zoledronic acid in delaying the onset of such events in patients with metastatic breast or prostate cancer.
* Serious adverse effects of denosumab include hypocalcemia and osteonecrosis of the jaw.
Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: email@example.com.